<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322006</url>
  </required_header>
  <id_info>
    <org_study_id>TJ004309STM102</org_study_id>
    <nct_id>NCT04322006</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of TJ004309 for Advanced Solid Tumor</brief_title>
  <official_title>A Phase I/II Study of Evaluating the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics and Curative Effect of Dose Escalation and Extension for Single Drug TJ004309 and PD-1 Monoclonal Antibody Injection Combine Treatment for Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Mab Biopharma Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Mab Biopharma Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase I/II study of single drug TJ004309 and PD-1 monoclonal antibody&#xD;
      injection combine treatment for Advanced solid tumor. This study include two stages. First&#xD;
      stage is dose escalation and second stage is dose extension. The purpose of part A is to&#xD;
      confirm the MTD or MED and the clinical dose. The purpose of part B is to observe the safety,&#xD;
      effectiveness, Pharmacokinetics, pharmacodynamics and biomarker properties for effective&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities(DLT)</measure>
    <time_frame>28days after first dose</time_frame>
    <description>The safety and tolerance of TJ004309</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>2 years</time_frame>
    <description>Maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MED</measure>
    <time_frame>2 years</time_frame>
    <description>Maximum effective dose (MED)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommend dose of TJ004309</measure>
    <time_frame>2 years</time_frame>
    <description>Recommend dose of TJ004309</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">221</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>TJ004309 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg/kg~20mg/kg TJ004309 Injection is administered once a week for a treatment cycle every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 monoclonal antibody injection</intervention_name>
    <description>15mg/kg~20mg/kg TJ004309 Injection in combination with PD-1 monoclonal antibody injection every 2 weeks for a treatment cycle every 28 days</description>
    <arm_group_label>TJ004309 Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ004309 Injection</intervention_name>
    <description>2mg/kg~20mg/kg TJ004309 Injection is administered once a week for a treatment cycle every 28 days</description>
    <arm_group_label>TJ004309 Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1&#xD;
&#xD;
          -  In the dose-escalation phase, subjects with advanced solid tumors that are&#xD;
             histologically or cytologically confirmed to be unresectable or have metastasized,&#xD;
             subjects with standard treatment failure or intolerance (disease progression, or&#xD;
             inability to tolerate chemotherapy, targeted therapy, etc.), or subjects without&#xD;
             effective treatment.&#xD;
&#xD;
          -  Synchronous dose expansion (will base on dose-escalation phase)&#xD;
&#xD;
          -  At least one measurable disease by modified RECIST 1.1 for immune based therapeutics&#xD;
             V1.1&#xD;
&#xD;
          -  Expected survival ≥ 3 months&#xD;
&#xD;
          -  Adequate organ function as defined by the following criteria:&#xD;
&#xD;
               -  Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5&#xD;
                  times upper limit of normal (ULN)&#xD;
&#xD;
               -  Total serum bilirubin ≤ 1.5 times the ULN&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 ×109/ L&#xD;
&#xD;
               -  Platelets ≥ 100×109/ L without transfusion support within 28 days prior to study&#xD;
                  treatment&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL without transfusion support within 14 days prior to study&#xD;
                  treatment&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 times the ULN or Creatinine clearance &gt; 30 mL/min by&#xD;
                  Cockcroft-Gault formula&#xD;
&#xD;
               -  International normalized ratio (INR) in normal range&#xD;
&#xD;
          -  Serum pregnancy test must be negative for childbearing female prior to study treatment&#xD;
&#xD;
          -  The man have reproductive ability or childbearing female (refers to men and women not&#xD;
             on birth control operation, and the menopause women), must use the highly effective&#xD;
             contraceptive methods (such as oral contraceptives, intrauterine contraceptive device,&#xD;
             abstemious sexual desire or barrier contraceptive method combined with spermicide)&#xD;
             during the study, and sustain contraception 6 months after the last dose&#xD;
&#xD;
          -  Willingness and ability to consent for self to participate in study and comply with&#xD;
             scheduled visits, treatment plan, laboratory tests, and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Prior T-cell therapy&#xD;
&#xD;
          -  Receipt of systemic anticancer therapy or ≥ 5 times the elimination half-life of the&#xD;
             drug has elapsed within 2 weeks prior to study treatment (Note: whichever is shorter&#xD;
             shall prevail.)&#xD;
&#xD;
          -  Exist ≥ 2 kinds of primary tumor, expect cured preinvasive carcinoma and basaloma.&#xD;
             (patients are not excluded if ≥ 5 years treatment with other tumor prior to study&#xD;
             treatment.)&#xD;
&#xD;
          -  Autoimmune disease requiring treatment within the past twelve months only requiring&#xD;
             related treatment replacement&#xD;
&#xD;
          -  Condition requiring systemic treatment with either corticosteroids (&gt;10 mg daily&#xD;
             prednisone equivalent) or other immunosuppressive medications more than 7 days within&#xD;
             14 days prior to study treatment (Note: inhaled and topical steroids, and adrenal&#xD;
             replacement steroid doses &gt; 10 mg daily prednisone equivalent, are permitted in the&#xD;
             absence of active autoimmune disease.)&#xD;
&#xD;
          -  Current treatment on another therapeutic clinical trial within 14 days prior to study&#xD;
             treatment&#xD;
&#xD;
          -  Major surgical procedure or significant traumatic injury within 4 weeks prior to study&#xD;
             treatment and no date of surgery (if applicable) or anticipated need for a major&#xD;
             surgical procedure planned during study treatment&#xD;
&#xD;
          -  Chest radiotherapy ≤ 4 weeks, wide field radiotherapy ≤ 4 weeks (defined as &gt; 50% of&#xD;
             volume of pelvic bones or equivalent) or palliative radiotherapy ≤ 2 weeks prior to&#xD;
             study treatment&#xD;
&#xD;
          -  Brain involvement with cancer, spinal cord compression, or carcinomatous meningitis,&#xD;
             or new evidence of brain or leptomeningeal disease, unless the lesion(s) have been&#xD;
             radiated or resected, are considered fully treated and inactive, are asymptomatic, and&#xD;
             no steroids have been administered for central nervous system disease over the 2 weeks&#xD;
             prior to study treatment&#xD;
&#xD;
          -  Known active viral or nonviral hepatitis or cirrhosis, except patients with Hepatitis&#xD;
             C infection and undetectable virus following treatment are eligible.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  Ascites or pericardial effusion that can not be control&#xD;
&#xD;
          -  History of or active interstitial lung disease&#xD;
&#xD;
          -  Hypertension is not well controlled by medication. Hypertension defined as blood&#xD;
             pressure (BP) systolic &gt; 150 or diastolic &gt; 90 mm Hg (Note: Initiation or adjustment&#xD;
             of antihypertensive medication prior to study entry is allowed provided that the&#xD;
             average of the three most recent BP readings prior to study enrollment is ≤150/90 mm&#xD;
             Hg.)&#xD;
&#xD;
          -  Cardiovascular diseases with clinical significance, include phase II-III cardiac&#xD;
             insufficiency defined by New York Heart Association, myocardial infarction (MI) within&#xD;
             3 months prior to study treatment, symptomatic congestive heart failure, cerebral&#xD;
             infarction within 3 months prior to study treatment, percutaneous transluminal&#xD;
             coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) within 6 months&#xD;
             prior to study treatment&#xD;
&#xD;
          -  Deep-venous thrombosis within 6 months prior to study treatment (except treated&#xD;
             without warfarin 2 weeks prior to study treatment)&#xD;
&#xD;
          -  Thrombolytic use (except to maintain IV catheters) within 10 days prior study&#xD;
             treatment&#xD;
&#xD;
          -  Any active infection requiring systemic treatment&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or may&#xD;
             interfere with the interpretation of study results and, in the judgment of the&#xD;
             Investigator, would make the patient inappropriate for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yilong Wu</last_name>
    <phone>020-83827812-21187</phone>
    <email>syylwu@live.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qing Zhou</last_name>
    <phone>020-83827812</phone>
    <email>gzzhouqing@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yilong Wu, Doctor</last_name>
      <email>syylwu@live.cn</email>
    </contact>
    <contact_backup>
      <last_name>Qing Zhou, Doctor</last_name>
      <email>gzzhouqing@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiuwei Cui, Doctor</last_name>
      <email>jdyycjw@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Zhang, Doctor</last_name>
      <email>syner2000@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

